Stay updated on Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Sign up to get notified when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.

Latest updates to the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe history now includes an added Revision: v3.4.2 and the previous funding-status notice was removed, with no changes to the actual study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check20 days agoChange DetectedAdded a government funding status notice and updated the page revision to v3.4.1, replacing v3.4.0.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page adds a glossary and color-coded highlights (green for additions, red for deletions) and updates the revision label to v3.4.0; the previous No FEAR Act data and v3.3.4 label were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check42 days agoChange DetectedThe page shows a revision label updated from v3.3.3 to v3.3.4 in the UI. There are no visible changes to the study history content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.3.3 was added and the entries for 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedThe page shows a new site revision (v3.3.2), replacing the older revision (v3.2.0), a UI/site version update that does not alter the study history content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.